Boston Scientific Corporation vs Fidelity National Information Servcs Inc — how do they compare? Boston Scientific Corporation trades at $43.2 (market cap $66.37B), while Fidelity National Information Servcs Inc trades at $41.2 (market cap $20.97B). The key difference: Boston Scientific Corporation is far larger — about 3.2× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.14% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | FIS | |
|---|---|---|
Market Cap | $66.37B | $20.97B |
Sector | Health | Technology |
52-Week High | $108.14 | $81.94 |
52-Week Low | $42.63 | $37.72 |
Enterprise Value | $75.94B | $41.37B |
Dividend Yield | — | 4.14% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
FIS trades at $41.93, down 0.12% on the day, with a bullish technical signal from moving averages and strong institutional support. The stock shows attractive valuation metrics with a P/E of 8.13 and P/S of 1.91, while recent earnings have generally beaten expectations. Positive news flow highlights FIS's leadership in AI-driven banking technology and cloud infrastructure, with upcoming Q2 2026 earnings on August 4, 2026, providing a near-term catalyst.
The outlook for FIS is positive given its low valuation, analyst consensus price target of $52.57 (25% upside), and strategic focus on digital banking growth. Key risks include execution challenges post-Worldpay divestiture and rising debt levels, but strong cash flow generation and dividend yield of approximately 1.05% support shareholder returns. Institutional sentiment remains bullish with 58% buy ratings.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →